



**World Health  
Organization**

20, AVENUE APPIA – CH-1211 GENEVA 27 – SWITZERLAND – TEL CENTRAL +41 22 791 2111 – FAX CENTRAL +41 22 791 3111 – WWW.WHO.INT

Tel. direct: +41 22 791 2246  
Fax direct: +41 22 791 47 30  
E-mail : prequalinspection@who.int

In reply please  
refer to: P5 447 3/SC/Sc

Your reference:

Dr Kamal Vashi  
General Manager - Operations  
Mangalam Drugs and Organics Ltd  
Plot No 187, G.I.D.C.  
Vapi 396 195  
Gujarat  
Inde

13 April 2011

Dear Dr Vashi,

**WHO Prequalification of Medicines Programme  
Closing of Inspection**

Thank you for your letter dated 22 February 2011 and for the corrective actions to the observations listed in the inspection report following the inspection as detailed below:

Name: Mangalam Drugs and Organics Ltd  
Address: Plot No 187, II Phase, G.I.D.C.  
Vapi 396 195, Gujarat  
India  
Date: 17 to 21 January 2011

The actions taken or proposed to be taken in relation to the observations listed in the WHO inspection report have been reviewed by the inspectors. In general, they are considered acceptable and will be verified during future inspections.:

The following APIs:


- Lumefantrine (APIMF100)
- Artemether (APIMF101, APIMF138)
- Artesunate (APIMF135)
- Amodiaquine HCl (APIMF134)

are considered to be manufactured in compliance with WHO GMPs for Active Pharmaceutical Ingredients.

Please do not hesitate to send an email to [prequalinspection@who.int](mailto:prequalinspection@who.int) should you require any further information regarding the close out of this inspection.

Yours sincerely,

P.P.

  
Dr A. J. van Zyl  
Head of Inspections  
Prequalification of Medicines Programme  
Quality Assurance & Safety: Medicines

منظمة الصحة العالمية • 世界卫生组织

Organisation mondiale de la Santé • Всемирная организация здравоохранения • Organización Mundial de la Salud